B. Metzler seel. Sohn & Co. AG Takes $2.48 Million Position in Elanco Animal Health Incorporated $ELAN

Key Points

• B. Metzler seel. Sohn & Co. AG acquired 100,736 Elanco shares in the second quarter, valued at approximately $2.48 million. Institutional investors collectively own 97.48% of the company.
• Elanco reported stronger-than-expected quarterly results, with EPS of $0.34 versus the $0.27 consensus estimate and revenue of $1.37 billion, up 10.2% year over year.
• Analyst sentiment remains positive, with a “Moderate Buy” consensus rating and an average price target of $29.09; insiders also purchased 63,198 shares worth roughly $1.47 million over the past 90 days.

B. Metzler seel. Sohn & Co. AG acquired a new stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 100,736 shares of the company's stock, valued at approximately $2,479,000.

A number of other large investors have also bought and sold shares of the business. NewEdge Advisors LLC lifted its stake in Elanco Animal Health by 133.7% in the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company's stock valued at $25,000 after buying an additional 627 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Elanco Animal Health in the 2nd quarter valued at $38,000. Root Financial Partners LLC lifted its position in Elanco Animal Health by 50.7% in the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company's stock valued at $40,000 after acquiring an additional 592 shares in the last quarter. Uniplan Investment Counsel Inc. acquired a new position in Elanco Animal Health in the 4th quarter worth $41,000. Finally, Torren Management LLC acquired a new position in Elanco Animal Health in the 4th quarter worth $46,000. 97.48% of the stock is owned by institutional investors.

Elanco Animal Health Trading Up 2.1%

Shares of NYSE:ELAN opened at $24.05 on Friday. The company's 50-day moving average price is $24.56 and its two-hundred day moving average price is $24.01. Elanco Animal Health Incorporated has a one year low of $17.11 and a one year high of $27.98. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10. The stock has a market capitalization of $12.02 billion, a PE ratio of -58.66, a price-to-earnings-growth ratio of 1.44 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.07. The company had revenue of $1.37 billion during the quarter, compared to analysts' expectations of $1.31 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.Elanco Animal Health's revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.26 EPS. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, equities analysts forecast that Elanco Animal Health Incorporated will post 1.12 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have issued reports on ELAN shares. Piper Sandler reissued an "overweight" rating on shares of Elanco Animal Health in a research note on Monday, June 29th. KeyCorp increased their price objective on Elanco Animal Health from $29.00 to $30.00 and gave the stock an "overweight" rating in a report on Thursday, August 6th. JPMorgan Chase & Co. lifted their target price on Elanco Animal Health from $28.00 to $30.00 and gave the company an "overweight" rating in a research report on Thursday, May 7th. UBS Group boosted their target price on Elanco Animal Health from $31.00 to $33.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Finally, Morgan Stanley upped their price target on Elanco Animal Health from $23.00 to $26.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $29.09.

Insiders Place Their Bets

In other news, Director Paul Herendeen purchased 10,000 shares of the company's stock in a transaction on Friday, August 7th. The shares were purchased at an average cost of $23.68 per share, with a total value of $236,800.00. Following the completion of the transaction, the director owned 111,687 shares of the company's stock, valued at $2,644,748.16. The trade was a 9.83% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Lawrence Erik Kurzius purchased 40,000 shares of the company's stock in a transaction on Thursday, August 20th. The shares were purchased at an average cost of $23.40 per share, for a total transaction of $936,000.00. Following the completion of the transaction, the director directly owned 188,647 shares of the company's stock, valued at approximately $4,414,339.80. This represents a 26.91% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased 63,198 shares of company stock valued at $1,473,109 in the last ninety days. 1.14% of the stock is currently owned by insiders.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source